iRen MEDICAL
Safe and digital home dialysis
iRen-MEDICAL’s Digital Dialysis Clinic, featuring the portable iDA system, lets patients safely and independently undergo dialysis anytime. With FDA clearance, it significantly reduces treatment time and revolutionizes the dialysis process.
By: Hezkiah Tsoory
Overfunding
Investment type:
Company Stage:
Category:
Medical Devices
Highlights
Highlights
An FDA cleared, Life-changing Portable Solution for Kidney Failure Patients Requiring Dialysis
iRen-MEDICAL has developed a sophisticated, portable, and automatic dialysis system that enables individuals with kidney failure to receive dialysis treatment anywhere and anytime. This state-of-the-art technology significantly enhances the quality of life for patients who previously had to endure multiple weekly trips to dialysis centers for lengthy 3-5 hour sessions, is now FDA cleared. By leveraging its innovative, patent-protected technology, iRen-MEDICAL improves the quality of at-home dialysis. Designed to reduce treatment-related infections and support patients in maintaining their regular daily routines, this advancement is poised to encourage a greater number of patients to opt for treatment outside traditional dialysis centers.
Revolutionizing Dialysis with a Cloud-Based Digital Clinic and personelized Treatment
With an innovative, intelligent computerized platform, iRen-MEDICAL has created a digital dialysis clinic that enables healthcare practitioners and dialysis patients to provide and receive personalized treatment from anywhere in the world. The platform securely stores information in a cloud-based system, analyzes it to generate customized alerts and insights, and automatically distributes this information to clinics for further monitoring by nurses and doctors. This approach ensures that each patient receives tailored care, enhancing the effectiveness of their treatment and reducing the need for frequent visits to physical dialysis clinics.
Funding and Strategic Partnerships with Israel’s Leading Tech Institutions and Investors
iRen-MEDICAL was established in collaboration with the Technion Research and Development Foundation (TRDF) and Trendlines Medical incubator, which specializes in medical technology investments, alongside experienced angel investors, the Arbelon Holdings Ltd fund and Rimoni Industries, which focuses on med-tech management and investments.
.png)
Prestigious Grants and Recognition from The European Commission – Horizon 2020 and the Israel Innovation Authority
The company has received R&D grants from the Israel Innovation Authority and won the prestigious Horizon 2020 European Funding for Research & Innovation from the European Commission, given to industry pioneers and companies displaying scientific excellence.
.png)
Successful Clinical Trials in Collaboration with Israel’s Largest HMO
iRen-MEDICAL has completed successful clinical trials in collaboration with Israel's largest HMO, "Clalit Health Services", conducted in Clalit hospitals throughout Israel.
FDA Clearance for U.S. Market
The Digital Dialysis Clinic that includes iDA has received FDA clearance, allowing the company to soon start large-scale commercial activities in the US and begin working in partnership with Clalit Health Services.
First Prize Winner of the "100k MedTech Startup Contest"
iRen-MEDICAL is the first prize winner of the prestigious "100k MedTech Startup Contest" organized by the mHealth scientific journal, which covers innovative medical technologies and breakthroughs in the telemedicine field, and supported by Medimor and the Baruch Padeh Medical Center, Poria. The first prize also awarded the company substantial funds.
.png)
Successful Business Model: Financial Benefits for Patients, Caregivers, Dialysis Organizations and Healthcare Systems
iRen-MEDICAL’s Digital Dialysis Clinic will instigate a financial revolution in the dialysis treatment market, by saving substantial costs for healthcare providers and insurance companies worldwide. This model empowers caregivers to support a higher number of patients through a secure, monitored and automated platform. This model also enables patients to maintain their professional routine due to the flexibility and reduction in treatment duration.
A Team Comprised of Leading Engineers and Medical Specialists
iRen-MEDICAL was founded by a strong team of world-class scientists and engineers with extensive expertise in the field of nephrology. The company’s scientific advisory board is comprised of nephrologists and professors holding senior clinical and academic positions at international dialysis organizations and major hospitals in Israel and abroad.
Pitch
Pitch
The Problem
Over 10% of the world's population suffers from chronic kidney disease, which can lead to kidney failure when the body fails to eliminate waste, toxins, and excess water from the blood. In such cases, dialysis treatment is required to prolong patients' lives by replacing kidney function until a kidney transplant is possible.
Traditionally, dialysis is performed in specialized centers or hospitals with dedicated dialysis departments. Patients must travel to these centers three times a week for treatment sessions lasting 3 to 5 hours, often accompanied by side effects such as fainting, fatigue, nausea, and vomiting. Many patients feel that dialysis dominates their lives and disrupts their daily routines.
Unlike hemodialysis, which is performed in dialysis centers, peritoneal dialysis (PD) can be done at home, offering a lower cost and fewer side effects. At-home dialysis provides a better patient experience and outlook on treatment, thereby improving their quality of life. However, only 12% of dialysis patients opt for PD. Currently, peritoneal dialysis at home requires a sterile environment due to the risk of abdominal infection. The treatment involves cumbersome equipment, significant effort, and time to prepare and operate, and lacks professional monitoring and management, making patients more susceptible to complications.
Additionally, the transition of clinical treatment and surveillance to digital interfaces and patients' familiar home environments has become a trend in recent years, especially following the COVID-19 pandemic, during which chronic patients were confined to their homes.
The dialysis treatment market has not seen significant innovations in over 30 years but is now on the brink of transformation, finally refusing to stay behind.
The Solution
iRen-MEDICAL’s innovation is a total game-changer in the global dialysis market, with their Digital Dialysis Clinic that includes iDA, a portable dialysis device that can be used anywhere, anytime, along with a smart digital platform for patient management. The computerized system enables continuous treatment monitoring by medical professionals, while the user-friendly dialysis device reduces infection risks and empowers patients to adhere to their treatment regimen. Together, these advancements significantly enhance the quality of life and quality of treatment for dialysis patients. For the first time, patients can maintain a full and active lifestyle, all while reducing costs for healthcare organizations and dialysis centers worldwide.
The Technology
iRen-MEDICAL’s automatic and portable dialysis system allows more people to enjoy the benefits of, at-home peritoneal dialysis.
The Digital Dialysis Clinic is comprised of:
- A portable dialysis device with a designated disposable cartridge and patient phone application.
- A portal for digital monitoring and treatment optimization
The cloud-based computerized platform connects patients with medical professionals that conduct ongoing monitoring of treatment progression to personalize treatment and prevent complications. The digital monitoring portal sends real-time alerts to both patients and the medical team. It also syncs with different devices, such as blood pressure monitors and digital scales, so information can be efficiently and reliably transferred.
The portable dialysis device, the Intelligent Dialysis Assistant (iDA), performs peritoneal dialysis (in the peritoneum). As opposed to hemodialysis, which takes hours to complete, the entire PD process, from start to finish, takes approximately 20 minutes.
How it works –in 5 steps:
- Wash hands & gather supplies
- Drop in the disposable cartridge and place the tubing
- Close the cover
- Connect the catheter
- Press 'Start'
IDA's Infection-Control Technology
- Automatic tube connections reduce unwanted handling errors
- Active flush process for every exchange is designed to eliminate contaminates
- Early detection of peritonitis enables early treatment to prevent infection deterioration
iRen-MEDICAL has successfully developed groundbreaking technology of fluid analysis recognized by the prestigious scientific committee of the American Society for Nephrology (ASN). This achievement places the company at the forefront of innovation, earning it widespread recognition.
iRen-MEDICAL’s Abstract Accepted for poster Presentation at ASN Kidney Week 2023
The poster presentation details the Intelligent Dialysis Assistant (iDA), iRen-MEDICAL's new electronic automated ambulatory PD exchange device, which is part of the company's Digital Dialysis Clinic. The iDA is designed to provide aseptic Peritoneal Dialysis (PD) exchanges and is equipped with an inline White Blood Cell sensor that can detect white blood cells (WBC) in the PD effluent in real-time, aiding in the early diagnosis of peritonitis.
This point-of-care testing system for detecting peritonitis using a sensor represents a promising approach that may improve the prompt diagnosis and treatment of peritonitis in PD patients.
Team
Team
|
B.Sc. Mechanical Engineering - Technion - Israel Institute of Technology; M.Sc. Management - New York University -Tandon School of Engineering. 20+ years’ experience R&D, international business, operations; former executive positions with PV Nanocell, D Medical Industries, MCS, Mentorwave, Power Paper. Hezkiah is a management executive in medical device and biotechnology ventures. He has strong background in technology, as well as in management, and creates a perfect combination to lead entrepreneurial technological ventures Mr. Tsoory recently co-founded liberDi, a company committed to providing a breakthrough solution with the potential to dramatically improve the lives of people with end-stage renal disease (ESRD). liberDi has developed an automated peritoneal dialysis (PD) system that is small and portable and addresses the adverse side effects associated with other currently available treatments. With a proven track record in • Forming international strategic collaborations • Strategic planning and execution • Bringing new products to market • Executing multidisciplinary R&D projects • Fundraising
|
|
Head, Department of Nephrology and Hypertension, Carmel Medical Center. President, Israeli Society of Nephrology and Hypertension. 20+ years’ experience as specialist in nephrology and hypertension Dr. Frajewicki started his training in Internal Medicine in Buenos Aires, Argentina. He completed his medical formation in the Department of Nephrology and Hypertension at the Carmel Medical Center affiliated to the Technion Institute of Technology in Haifa. He currently is the Head of the Department. His main interests are focusing on clinical and basic research on dialysis, both hemo and peritoneal dialysis. By now Dr Frajewicki is the President of the Israeli Society of Nephrology and Hypertension, dealing with issues of public health in Israel.
|
|
Head of the Institute of Nephrology, Rabin Medical Center (Beilinson & Hasharon hospitals), Petah Tikva, Israel; 30 years clinical and research experience in the field of Nephrology in general, and in peritoneal dialysis in particular Prof Avry Chagnac is an internationally recognized researcher in nephrology. He previously served as head of the Department of Nephrology at Rabin Medical Center and Tel Aviv University. He has extensive clinical and research experience in the field of nephrology in general, and in peritoneal dialysis in particular. He has authored or co-authored more than 100 publications. He served as chairman of the Israeli Peritoneal Dialysis Committee. In 2018 he was awarded a prize by The Israeli Society of Nephrology for his contribution to research in nephrology.
|
|
Head of peritoneal dialysis unit, Imperial College Kidney and Transplant Centre, Hammersmith Hospital, London, UK. Co-organiser of UK PD Academy. Extensive research and education related to outcomes of older patients on dialysis. Chair of the guidelines committee, International Society of Peritoneal Dialysis A clinical nephrologist with an international reputation in peritoneal dialysis (PD). She is currently chair of the clinical guideline committee for the International Society of Peritoneal Dialysis. She is the head of the PD programme at Hammersmith Hospital, London, UK (currently 150 patients) and is an honorary professor of renal medicine at Imperial College London. She has been the lead investigator of key multicentre studies related to PD including the European APD Outcome Study (EAPOS). She initiated the development of assisted PD in the UK. She has been on the organising faculty of the UK PD Academy since its initiation in 2000, published more than 150 papers and published several books, including the Oxford Handbook of Dialysis (now in 4th edition).
|
|
Served for almost 3 decades on the board of B. Braun Group of companies and as CEO of B. Braun North America. He is currently Executive Advisor to Water Street Healthcare Partners LLP in Chicago. Mr. Neubauer has advanced meaningful change and innovation in the healthcare industry as a long-time Board Member of AdvaMed and other healthcare organizations, for which he has received numerous awards.
|
|
a Certified Public Accountant, with over 20 years of experience in CFO and financial advisory positions in technology and med-tech sectors. Holds a L.L.B. and B.B. degrees in business administration.
|
